Burkly Linda sold $2K of EDIT

Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 731 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burkly Linda
Published Jun 5, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
high confidence
Mentioned
$EDIT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

This is a disclosure of a completed transaction, not a new operational or clinical milestone. The planned nature reduces interpretive weight for near-term price action.

02

Market read

Traders may note insider activity, but the planned 10b5-1 open-market sale provides limited incremental information for valuation or catalysts.

03

What to watch

The filing doesn’t indicate intent or valuation view; the sale size ($1,974.50) is small relative to typical institutional flows and may be routine diversification.

Relevance 6/10Novelty 2/10Timing: Filed 2026-06-05; sale executed 2026-06-03.

Background

SEC Form 4 reports insider transactions; this one is an officer (EVP, Chief Scientific Officer) open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$EDITNeutralHigh confidence
Context

EDIT disclosed an officer open-market sale: Burkly Linda sold 731 shares at $2.7011 on 2026-06-03 under a 10b5-1 plan.

Expected impact

Minimal near-term impact; any move would be more likely driven by broader biotech sentiment than this Form 4.

Evidence & confidence

Form 4 shows a routine, planned insider sale with no accompanying corporate event, guidance change, or new clinical/contract catalyst.

Market effects

None—single-company planned insider sale without new biotech/regulatory/clinical information.

None.

None.

Counterpoint

Even planned 10b5-1 sales can coincide with internal risk management; traders may still watch for follow-on selling or reduced insider conviction.

Key entities

  • Editas Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Burkly Linda

    EVP, Chief Scientific Officer who sold 731 shares of EDIT.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EDITMed

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.